Uprooted by the success of its seed-and-feed approach to growing scientific research projects into a garden of rare genetic disease companies, a Palo Alto organization is planting itself anew with a fertilizing round of nearly $300 million.
BridgeBio Inc. raised $299.2 million, the Palo Alto company said Wednesday, to support 18 projects and add three to five new programs over the next two years, said CEO Neil Kumar. The round was led by exiting investors KKR & Co. LP and Viking Global Investors…
